Archive for the ‘Anti-Infectives’ Category

IMMUNIZATIONS FOR TRAVEL HEALTHY SAFETY: MENINGOCOCCAL VACCINATION

Tuesday, December 28th, 2010
Meningococcal vaccination may benefit travelers to areas where Neisseria meningitidis is endemic or where there is an outbreak, especially if extended contact with local persons is anticipated. Up to 10% of the population of countries with endemic meningococcal disease might be asymptomatic carriers. In sub-Saharan Africa, epidemics of serogroups A or С meningococcal disease occur frequently during the dry season (December through June), particularly in the savannah areas extending from Senegal to Ethiopia in the so-called “meningitis belt”. Meningococcal vaccine is recommended for travel to this area. The vaccine is required for pilgrims entering Mecca, Saudi Arabia during the Hajj. Epidemics of meningococcal disease have occasionally been reported in Kenya, Tanzania, Burundi, and Mongolia. The CDC web site can provide updated information about recent epidemics and review the geographic areas for which vaccine is recommended.
The currently available meningococcal vaccine (Menomune, Aventis Pasteur) is effective only against serogroups A, C, Y, and W-135. Primary immunization in persons 2 years and older consists of a single 0.5 mL dose given by subcutaneous injection, and this confers immunity for at least 3 years. Protective levels of antibody are achieved in 7 to 10 days. Pain at the injection site is the most commonly reported adverse reaction. Vaccination is not contraindicated in pregnancy. Revaccination may be considered within 3 to 5 years for continued exposure.
*187/348/5*

IMMUNIZATIONS FOR TRAVEL HEALTHY SAFETY: MENINGOCOCCAL VACCINATIONMeningococcal vaccination may benefit travelers to areas where Neisseria meningitidis is endemic or where there is an outbreak, especially if extended contact with local persons is anticipated. Up to 10% of the population of countries with endemic meningococcal disease might be asymptomatic carriers. In sub-Saharan Africa, epidemics of serogroups A or С meningococcal disease occur frequently during the dry season (December through June), particularly in the savannah areas extending from Senegal to Ethiopia in the so-called “meningitis belt”. Meningococcal vaccine is recommended for travel to this area. The vaccine is required for pilgrims entering Mecca, Saudi Arabia during the Hajj. Epidemics of meningococcal disease have occasionally been reported in Kenya, Tanzania, Burundi, and Mongolia. The CDC web site can provide updated information about recent epidemics and review the geographic areas for which vaccine is recommended.The currently available meningococcal vaccine (Menomune, Aventis Pasteur) is effective only against serogroups A, C, Y, and W-135. Primary immunization in persons 2 years and older consists of a single 0.5 mL dose given by subcutaneous injection, and this confers immunity for at least 3 years. Protective levels of antibody are achieved in 7 to 10 days. Pain at the injection site is the most commonly reported adverse reaction. Vaccination is not contraindicated in pregnancy. Revaccination may be considered within 3 to 5 years for continued exposure.*187/348/5*